An Investigation and Analysis of Literature on Stem Cell and Regenerative Medicine Industry in China

Abstract

The latest report from the National Bureau of Statistics, "China's economic and social development in 2016", shows that the number of people aged 60 and above is approximately 230 million (i.e., 16.7% of the population). By 2050, this age-group will increase to 400 million, accounting for more than 30% of the population. In China, this dramatic aging trend has endangered people's health. Major disorders such as tissue and organ damage, cardiovascular and other functional organ failures, degenerative diseases, and cancer are closely related to aging. Traditional treatments such as drug therapy and surgery often have little effect on such diseases, and fail to meet the growing medical needs of this age-group. Stem cell-based regenerative medicine is expected to become the third treatment option after drug therapy and surgery. With the increasing financial supports and investments in China recent years, a series of important progress have been made to stem cells and regenerative medicine. In this issue, we investigated the stem cell and regenerative medicine industry in the world and china, such as research literature and research institutions distribution.